255 related articles for article (PubMed ID: 23921866)
1. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
Hawk AF; Chang EY; Shields SM; Simpson KN
Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
[TBL] [Abstract][Full Text] [Related]
2. Costs and benefits of non-invasive fetal RhD determination.
Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
[TBL] [Abstract][Full Text] [Related]
3. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
[TBL] [Abstract][Full Text] [Related]
4. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
Moise KJ
Obstet Gynecol; 2013 Dec; 122(6):1306. PubMed ID: 24264705
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
6. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
[TBL] [Abstract][Full Text] [Related]
9. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
Cortey A; Brossard Y
J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
[TBL] [Abstract][Full Text] [Related]
11. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
[TBL] [Abstract][Full Text] [Related]
13. Cell free fetal DNA to triage antenatal rhesus immune globulin: Is it really cost-effective in the United States?
Moise KJ; Hashmi SS; Markham K; Argoti PS; Bebbington M
Prenat Diagn; 2019 Feb; 39(3):238-247. PubMed ID: 30610742
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis.
Gordon LG; Hyland CA; Hyett JA; O'Brien H; Millard G; Flower RL; Gardener GJ
Prenat Diagn; 2017 Dec; 37(12):1245-1253. PubMed ID: 29096422
[TBL] [Abstract][Full Text] [Related]
15. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study.
Benachi A; Delahaye S; Leticee N; Jouannic JM; Ville Y; Costa JM
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):28-32. PubMed ID: 22386678
[TBL] [Abstract][Full Text] [Related]
16. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis.
Clausen FB; Christiansen M; Steffensen R; Jørgensen S; Nielsen C; Jakobsen MA; Madsen RD; Jensen K; Krog GR; Rieneck K; Sprogøe U; Homburg KM; Grunnet N; Dziegiel MH
Transfusion; 2012 Apr; 52(4):752-8. PubMed ID: 21995641
[TBL] [Abstract][Full Text] [Related]
17. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population?
Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M
Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934
[TBL] [Abstract][Full Text] [Related]
18. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
[TBL] [Abstract][Full Text] [Related]
19. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed.
van der Schoot CE; Tax GH; Rijnders RJ; de Haas M; Christiaens GC
Transfus Med Rev; 2003 Jan; 17(1):31-44. PubMed ID: 12522770
[TBL] [Abstract][Full Text] [Related]
20. Determination of fetal RHD type in plasma of RhD negative pregnant women.
Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
